PUBLISHER: Blueweave Consulting | PRODUCT CODE: 1566051
PUBLISHER: Blueweave Consulting | PRODUCT CODE: 1566051
Europe Genomic Cancer Panel and Profiling Market, By Technology; By Application; By End User; By Region, Trend Analysis, Competitive Landscape & Forecast, 2019-2030
Europe Genomic Cancer Panel and Profiling Market Booming to Surpass Value of USD 4.7 Billion by 2030
Europe Genomic Cancer Panel and Profiling Market is flourishing due to the growing awareness about the benefits of genomic testing, a surge in demand for personalized medicine, and supportive government initiatives.
BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Europe Genomic Cancer Panel and Profiling Market size by value at USD 2.62 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Europe Genomic Cancer Panel and Profiling Market size to expand at a CAGR of 9.10% reaching a value of USD 4.71 billion by 2030. The Genomic Cancer Panel and Profiling Market across Europe is propelled by the advancements in genomic sequencing technologies, rising cancer incidence, increased adoption of precision oncology, investments in research and development, and collaborative efforts between industry stakeholders. These factors collectively contribute to the substantial growth potential of the European Genomic Cancer Panel and Profiling Market.
Opportunity - Advancements in Technology
Next-generation sequencing (NGS) technologies represent a transformative advancement in genomic analysis, fundamentally changing the landscape of cancer profiling. These cutting-edge platforms revolutionize the decoding of genetic information, providing unparalleled speed, accuracy, and cost-effectiveness compared to traditional methods. NGS enables simultaneous analysis of multiple genes within a single run, allowing for comprehensive profiling of cancer genomes and detection of various genetic alterations, including point mutations, insertions, deletions, and copy number variations. This thorough interrogation aids in identifying driver mutations and oncogenic pathways, paving the way for personalized treatment strategies tailored to each patient's unique genetic profile. Rapid advancements in NGS have spurred its widespread adoption in clinical and research settings, with continuous improvements in sequencing platforms, bioinformatics tools, and data analysis algorithms enhancing performance and reliability. Consequently, NGS has become indispensable for oncologists, facilitating informed clinical decisions and optimized treatment outcomes. Additionally, the cost-effectiveness of NGS has lowered barriers to genomic cancer profiling, broadening access for healthcare providers and patients. The decreasing costs and scalability of NGS platforms have democratized genomic medicine, enabling greater access to advanced diagnostic technologies and personalized treatment options for cancer patients across Europe.
United Kingdom Leads Europe Genomic Cancer Panel and Profiling Market
United Kingdom's supportive regulatory framework and robust healthcare system have fueled a rapid increase in the adoption of genomic testing within clinical practice. The National Institute for Health and Care Excellence (NICE) has played a key role in guiding the integration of genomic technologies into cancer care, boosting confidence among healthcare providers and driving market expansion. Through initiatives like the Genomes Project and the Genomics England program, the UK has made significant investments in genomic medicine. These efforts have accelerated genomic research and data collection, providing valuable insights into the genetic basis of cancer. It has enabled the routine clinical use of genomic profiling, solidifying the UK's position as a global leader in the field and contributing to its dominant position in Europe Genomic Cancer Panel and Profiling Market.
Impact of Escalating Geopolitical Tensions on Europe Genomic Cancer Panel and Profiling Market
Europe Genomic Cancer Panel and Profiling Market may face significant challenges from intensifying geopolitical tensions across the world. Disruptions in supply chains, increased operational costs, and heightened uncertainty can hinder industry advancement. Trade barriers and regulatory changes may limit access to essential genomic technologies, impeding research and development efforts. Additionally, governments may prioritize national security over healthcare funding, potentially diverting resources away from critical genomic initiatives. These factors could collectively slow innovation, reduce investment, and ultimately impact the availability and adoption of advanced genomic solutions for cancer diagnostics and personalized treatment.
Competitive Landscape
Europe Genomic Cancer Panel and Profiling Market is fragmented, with numerous players serving the market. The key players dominating Europe Genomic Cancer Panel and Profiling Market include F. Hoffmann-La Roche Ltd, ARUP Laboratories, Agilent, Caris Life Sciences, Thermo Fisher Scientific, Danaher Corporation, Exact Sciences, EUCOPE, Guardant Health, Illumina, Merck & Co., Inc., and Novartis. The key marketing strategies adopted by the players are facility expansion, product diversification, alliances, collaborations, partnerships, and acquisitions to expand their customer reach and gain a competitive edge in the overall market.
The report's in-depth analysis provides information about growth potential, upcoming trends, and Europe Genomic Cancer Panel and Profiling Market statistics. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Europe Genomic Cancer Panel and Profiling Market along with industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyses the growth drivers, challenges, and competitive dynamics of the market.
Table of Contents
1. Research Framework
- 1.1. Research Objective
- 1.2. Product Overview
- 1.3. Market Segmentation
2. Executive Summary
3. Europe Genomic Cancer Panel and Profiling Market Insights
- 3.1. Industry Value Chain Analysis
- 3.2. DROC Analysis
- 3.2.1. Growth Drivers
- 3.2.1.1. Growing awareness of the benefits of genomic testing
- 3.2.1.2. Increasing demand for personalized medicine
- 3.2.1.3. Favorable government policies to support the development of genomic medicine
- 3.2.2. Restraints
- 3.2.2.1. High costs associated with genomic testing
- 3.2.2.2. Increasing concerns about data privacy and security
- 3.2.2.3. Lack of standardized guidelines
- 3.2.3. Opportunities
- 3.2.3.1. Advancements in technology
- 3.2.3.2. Expanding applications of genomic testing in various cancer types and stages
- 3.2.3.3. Integration with electronic health records
- 3.2.4. Challenges
- 3.2.4.1. Securing reimbursement for genomic testing
- 3.2.4.2. Addressing ethical concerns related to genomic testing
- 3.2.1. Growth Drivers
- 3.3. Technological Advancements/Recent Developments
- 3.4. Regulatory Framework
- 3.5. Porter's Five Forces Analysis
- 3.5.1. Bargaining Power of Suppliers
- 3.5.2. Bargaining Power of Buyers
- 3.5.3. Threat of New Entrants
- 3.5.4. Threat of Substitutes
- 3.5.5. Intensity of Rivalry
4. Europe Genomic Cancer Panel and Profiling Market: Marketing Strategies
5. Europe Genomic Cancer Panel and Profiling Market: Pricing Analysis
6. Europe Genomic Cancer Panel and Profiling Market Overview
- 6.1. Market Size & Forecast, 2019-2030
- 6.1.1. By Value (USD Billion)
- 6.2. Market Share and Forecast
- 6.2.1. By Technology
- 6.2.1.1. Next-Generation Sequencing (NGS)
- 6.2.1.2. Polymerase Chain Reaction (PCR)
- 6.2.1.3. Fluorescence In-Situ Hybridization (FISH)
- 6.2.1.4. Immunohistochemistry (IHC)
- 6.2.1.5. Others (CRISPR, Liquid Biopsy Technologies)
- 6.2.2. By Application
- 6.2.2.1. Clinical
- 6.2.2.2. Research
- 6.2.3. By End User
- 6.2.3.1. Hospitals
- 6.2.3.2. Clinical & Diagnostic Laboratories
- 6.2.3.3. Research & Academic Institutes
- 6.2.3.4. Others
- 6.2.4. By Region
- 6.2.4.1. Germany
- 6.2.4.2. United Kingdom
- 6.2.4.3. Italy
- 6.2.4.4. France
- 6.2.4.5. Spain
- 6.2.4.6. Belgium
- 6.2.4.7. Russia
- 6.2.4.8. The Netherlands
- 6.2.4.9. Rest of Europe
- 6.2.1. By Technology
7. Germany Genomic Cancer Panel and Profiling Market
- 7.1. Market Size & Forecast, 2019-2030
- 7.1.1. By Value (USD Billion)
- 7.2. Market Share & Forecast
- 7.2.1. By Technology
- 7.2.2. By Application
- 7.2.3. By End User
8. United Kingdom Genomic Cancer Panel and Profiling Market
- 8.1. Market Size & Forecast, 2019-2030
- 8.1.1. By Value (USD Billion)
- 8.2. Market Share & Forecast
- 8.2.1. By Technology
- 8.2.2. By Application
- 8.2.3. By End User
9. Italy Genomic Cancer Panel and Profiling Market
- 9.1. Market Size & Forecast, 2019-2030
- 9.1.1. By Value (USD Billion)
- 9.2. Market Share & Forecast
- 9.2.1. By Technology
- 9.2.2. By Application
- 9.2.3. By End User
10. France Genomic Cancer Panel and Profiling Market
- 10.1. Market Size & Forecast, 2019-2030
- 10.1.1. By Value (USD Billion)
- 10.2. Market Share & Forecast
- 10.2.1. By Technology
- 10.2.2. By Application
- 10.2.3. By End User
11. Spain Genomic Cancer Panel and Profiling Market
- 11.1. Market Size & Forecast, 2019-2030
- 11.1.1. By Value (USD Billion)
- 11.2. Market Share & Forecast
- 11.2.1. By Technology
- 11.2.2. By Application
- 11.2.3. By End User
12. Belgium Genomic Cancer Panel and Profiling Market
- 12.1. Market Size & Forecast, 2019-2030
- 12.1.1. By Value (USD Billion)
- 12.2. Market Share & Forecast
- 12.2.1. By Technology
- 12.2.2. By Application
- 12.2.3. By End User
13. Russia Genomic Cancer Panel and Profiling Market
- 13.1. Market Size & Forecast, 2019-2030
- 13.1.1. By Value (USD Billion)
- 13.2. Market Share & Forecast
- 13.2.1. By Technology
- 13.2.2. By Application
- 13.2.3. By End User
14. The Netherlands Genomic Cancer Panel and Profiling Market
- 14.1. Market Size & Forecast, 2019-2030
- 14.1.1. By Value (USD Billion)
- 14.2. Market Share & Forecast
- 14.2.1. By Technology
- 14.2.2. By Application
- 14.2.3. By End User
15. Rest of Europe Genomic Cancer Panel and Profiling Market
- 15.1. Market Size & Forecast, 2019-2030
- 15.1.1. By Value (USD Billion)
- 15.2. Market Share & Forecast
- 15.2.1. By Technology
- 15.2.2. By Application
- 15.2.3. By End User
16. Competitive Landscape
- 16.1. List of Key Players and Their Offerings
- 16.2. Europe Genomic Cancer Panel and Profiling Market Share Analysis, 2023
- 16.3. Competitive Benchmarking, By Operating Parameters
- 16.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
17. Impact of Escalating Geopolitical Tensions on Europe Genomic Cancer Panel and Profiling Market
18. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)
- 18.1. F. Hoffmann-La Roche Ltd
- 18.2. ARUP Laboratories
- 18.3. Agilent
- 18.4. Caris Life Sciences
- 18.5. Thermo Fisher Scientific
- 18.6. Danher Corporation
- 18.7. Exact Sciences
- 18.8. EUCOPE
- 18.9. Guardant Health
- 18.10. Illumina
- 18.11. Merck & Co., Inc.
- 18.12. Novartis
- 18.13. Other Prominent Players
19. Key Strategic Recommendations
20. Research Methodology
- 20.1. Qualitative Research
- 20.1.1. Primary & Secondary Research
- 20.2. Quantitative Research
- 20.3. Market Breakdown & Data Triangulation
- 20.3.1. Secondary Research
- 20.3.2. Primary Research
- 20.4. Breakdown of Primary Research Respondents, By Country
- 20.5. Assumptions & Limitations
*Financial information of non-listed companies can be provided as per availability.
**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable
List of Figures
- Figure 1 Europe Genomic Cancer Panel and Profiling Market Segmentation
- Figure 2 Europe Genomic Cancer Panel and Profiling Market Value Chain Analysis
- Figure 3 Company Market Share Analysis, 2023
- Figure 4 Europe Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019-2030
- Figure 5 Europe Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019-2030
- Figure 7 Europe Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019-2030
- Figure 8 Europe Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019-2030
- Figure 10 Europe Genomic Cancer Panel and Profiling Market Share, By Country, By Value, 2019-2030
- Figure 11 Germany Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019-2030
- Figure 12 Germany Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019-2030
- Figure 13 Germany Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019-2030
- Figure 14 Germany Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019-2030
- Figure 15 United Kingdom Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019-2030
- Figure 16 United Kingdom Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019-2030
- Figure 17 United Kingdom Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019-2030
- Figure 18 United Kingdom Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019-2030
- Figure 19 Italy Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019-2030
- Figure 20 Italy Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019-2030
- Figure 21 Italy Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019-2030
- Figure 22 Italy Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019-2030
- Figure 23 France Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019-2030
- Figure 24 France Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019-2030
- Figure 25 France Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019-2030
- Figure 26 France Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019-2030
- Figure 27 Spain Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019-2030
- Figure 28 Spain Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019-2030
- Figure 29 Spain Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019-2030
- Figure 30 Spain Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019-2030
- Figure 31 Belgium Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019-2030
- Figure 32 Belgium Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019-2030
- Figure 33 Belgium Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019-2030
- Figure 34 Belgium Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019-2030
- Figure 35 Russia Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019-2030
- Figure 36 Russia Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019-2030
- Figure 37 Russia Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019-2030
- Figure 38 Russia Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019-2030
- Figure 31 The Netherlands Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019-2030
- Figure 32 The Netherlands Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019-2030
- Figure 33 The Netherlands Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019-2030
- Figure 34 The Netherlands Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019-2030
- Figure 43 Rest of Europe Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019-2030
- Figure 44 Rest of Europe Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019-2030
- Figure 45 Rest of Europe Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019-2030
- Figure 46 Rest of Europe Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019-2030
List of Tables
- Table 1 Europe Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019-2030
- Table 2 Europe Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019-2030
- Table 3 Europe Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019-2030
- Table 4 Europe Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019-2030
- Table 5 Europe Genomic Cancer Panel and Profiling Market Share, By Country, By Value, 2019-2030
- Table 6 Germany Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019-2030
- Table 7 Germany Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019-2030
- Table 8 Germany Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019-2030
- Table 9 Germany Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019-2030
- Table 10 United Kingdom Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019-2030
- Table 11 United Kingdom Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019-2030
- Table 12 United Kingdom Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019-2030
- Table 13 United Kingdom Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019-2030
- Table 14 Italy Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019-2030
- Table 15 Italy Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019-2030
- Table 16 Italy Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019-2030
- Table 17 Italy Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019-2030
- Table 18 France Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019-2030
- Table 19 France Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019-2030
- Table 20 France Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019-2030
- Table 21 France Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019-2030
- Table 22 Spain Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019-2030
- Table 23 Spain Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019-2030
- Table 24 Spain Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019-2030
- Table 25 Spain Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019-2030
- Table 26 Belgium Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019-2030
- Table 27 Belgium Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019-2030
- Table 28 Belgium Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019-2030
- Table 29 Belgium Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019-2030
- Table 30 Russia Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019-2030
- Table 31 Russia Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019-2030
- Table 32 Russia Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019-2030
- Table 33 Russia Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019-2030
- Table 34 The Netherlands Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019-2030
- Table 35 The Netherlands Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019-2030
- Table 36 The Netherlands Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019-2030
- Table 37 The Netherlands Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019-2030
- Table 38 Rest of Europe Genomic Cancer Panel and Profiling Market Size, By Value (USD Billion), 2019-2030
- Table 39 Rest of Europe Genomic Cancer Panel and Profiling Market Share, By Technology, By Value, 2019-2030
- Table 40 Rest of Europe Genomic Cancer Panel and Profiling Market Share, By Application, By Value, 2019-2030
- Table 41 Rest of Europe Genomic Cancer Panel and Profiling Market Share, By End User, By Value, 2019-2030
- Table 42 F. Hoffmann-La Roche Ltd Company Overview
- Table 43 F. Hoffmann-La Roche Ltd Financial Overview
- Table 44 ARUP Laboratories Company Overview
- Table 45 ARUP Laboratories Financial Overview
- Table 46 Agilent Company Overview
- Table 47 Agilent Financial Overview
- Table 48 Caris Life Sciences Company Overview
- Table 49 Caris Life Sciences Financial Overview
- Table 50 Thermo Fisher Scientific Company Overview
- Table 51 Thermo Fisher Scientific Financial Overview
- Table 52 Danher Corporation Company Overview
- Table 53 Danher Corporation Financial Overview
- Table 54 Exact Sciences Company Overview
- Table 55 Exact Sciences Financial Overview
- Table 56 EUCOPE Company Overview
- Table 57 EUCOPE Financial Overview
- Table 58 Guardant Health Company Overview
- Table 59 Guardant Health Financial Overview
- Table 60 Illumina Company Overview
- Table 61 Illumina Financial Overview
- Table 62 Merck & Co., Inc. Company Overview
- Table 63 Merck & Co., Inc. Financial Overview
- Table 64 Novartis Company Overview
- Table 65 Novartis Financial Overview
